Polymorphism in the CCR5 gene promoter and HIV-1 infection in North Indians

被引:34
|
作者
Kaur, Gurvinder
Singh, P.
Rapthap, C. C.
Kumar, N.
Vajpayee, M.
Sharma, S. K.
Wanchu, A.
Mehra, N. K.
机构
[1] All India Inst Med Sci, Dept Transplant Immunol & Immunogenet, New Delhi 110029, India
[2] All India Inst Med Sci, Dept Microbiol, New Delhi 110029, India
[3] All India Inst Med Sci, Dept Med, New Delhi 110029, India
[4] Post Grad Inst Med Educ & Res, Dept Internal Med, Chandigarh, India
关键词
chemokine receptors; polymorphism; HIV-1; CCR5; AIDS;
D O I
10.1016/j.humimm.2007.01.016
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The clinical course and outcome of human immunodeficiency virus-1 (HIV-1) infection are highly variable among individuals. CCR5 is the primary coreceptor that mediates entry of HIV-1 (R5) into permissive host cells. In this study, five SNPs (59029G/A, 59353T/C, 59356C/T, 59402A/G, and 59653C/T) in the promoter region and a deletion of 32 bp (Delta 32) in the CCR5 gene were evaluated in 180 chronically HIV-1-infected North Indians. The study showed the following: (1) the protective CCR5 Delta 32 allele was absent; (2) the frequency of CCR5*59402A allele in the HIV-infected people (66.4%) was higher than in healthy subjects (57.1%, p = 0.027) and in the CDC stage C patients (76%) versus stages A and B patients together (60%; p = 0.002); (3) homozygous CCR5*59402 AA genotype was significantly increased in the seropositive subjects (46.1%) compared with healthy control subjects (30.2%; p = 0.008) and in the CDC stage C patients (59.2%) compared with stage A and B subjects (37.6%, P = 0.007); and (4) an increased frequency of homozygous ACCAC haplotype was present in the seropositive stage C patients (32.4% versus 15.6% in patients in stages A plus B (p = 0.013). These observations suggest an association of CCR5*59402A with increased likelihood of acquisition of HIV-1 and development of AIDS in the Asian Indian population. Further studies are required to confirm these findings and understand the effect of CCR5 polymorphisms on the outcome of HIV-1 infection.
引用
收藏
页码:454 / 461
页数:8
相关论文
共 50 条
  • [41] HIV-1 CCR5 gene therapy will fail unless it is combined with a suicide gene
    Pandit, Aridaman
    de Boer, Rob J.
    SCIENTIFIC REPORTS, 2015, 5
  • [42] The global distribution of CCR5 delta 32 polymorphism: role in HIV-1 protection
    Anuroopa Gupta
    Harish Padh
    BMC Infectious Diseases, 12 (Suppl 1)
  • [43] CCR5 Chemokine Receptor Polymorphism in Patients With HIV-1 From Western India
    Shankarkumar, Aruna
    Shankarkumar, Umapathy
    Ghosh, Kanjaksha
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 57 (02) : E21 - E21
  • [44] Variation of CCR5AS lncRNA Enhances HIV-1 Infection Through Regulation of CCR5 Expression
    Zou, Sen
    VIRAL IMMUNOLOGY, 2020, 33 (08) : 536 - 538
  • [45] Choosing CCR5 or Rev siRNA in HIV-1
    Arteaga, HJ
    Hinkula, J
    van Dijk-Härd, I
    Dilber, MS
    Wahren, B
    Christensson, B
    Mohamed, AJ
    Smith, CIE
    NATURE BIOTECHNOLOGY, 2003, 21 (03) : 230 - 231
  • [46] CCR5 monoclonal antibodies for HIV-1 therapy
    Olson, William C.
    Jacobson, Jeffrey M.
    CURRENT OPINION IN HIV AND AIDS, 2009, 4 (02) : 104 - 111
  • [47] Choosing CCR5 or Rev siRNA in HIV-1
    H. Jose Arteaga
    Jorma Hinkula
    Iris van Dijk-Härd
    M. Sirac Dilber
    Britta Wahren
    Birger Christensson
    Abdalla J. Mohamed
    C. I. Edvard Smith
    Nature Biotechnology, 2003, 21 : 230 - 231
  • [48] Role of CCR5 59029 A/G promoter polymorphism in the development of dengue infection
    Fernandez-Mestre, Mercedes T.
    Ogando, Violeta
    Layrisse, Zulay
    TISSUE ANTIGENS, 2009, 73 (05): : 403 - 404
  • [49] Adverse effect of the CCR5 promoter-2459A allele on HIV-1 disease progression
    Knudsen, TB
    Kristiansen, TB
    Katzenstein, TL
    Eugen-Olsen, J
    JOURNAL OF MEDICAL VIROLOGY, 2001, 65 (03) : 441 - 444
  • [50] Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection
    Kim, D
    Wang, LP
    Caldwell, CG
    Chen, P
    Finke, PE
    Oates, B
    MacCoss, M
    Mills, SG
    Malkowitz, L
    Gould, SL
    DeMartino, JA
    Springer, MS
    Hazuda, D
    Miller, M
    Kessler, J
    Danzeisen, R
    Carver, G
    Carella, A
    Holmes, K
    Lineberger, J
    Schleif, WA
    Emini, EA
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (24) : 3099 - 3102